Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV is a biotechnology company focused on developing medicines for oncology and immunology. Its pipeline includes GLPG3667, a therapy in phase 2 clinical trials for dermatomyositis and systemic lupus erythematosus. The company also develops CAR-T cell therapies manufactured at the point of care: GLPG5101 targets CD19 for relapsed/refractory non-Hodgkin lymphoma (phase 1/2), and GLPG5301 targets BCMA for relapsed/refractory multiple myeloma (phase 1/2). Lakefront operates primarily in the United States and Europe and has a collaboration agreement with Gilead Sciences, Inc.

Lakefront Biotherapeutics NV is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol LKFT. Its shares trade in US dollars (USD). The company is headquartered in Mechelen, Belgium, but its stock is traded on a US exchange, making it accessible to international investors.

Lakefront Biotherapeutics NV operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies, particularly in oncology (cancer) and immunology (immune system disorders). Its pipeline includes both small molecule drugs and cell therapies, reflecting the cutting-edge nature of the biotech field.

Lakefront Biotherapeutics NV is headquartered in Mechelen, Belgium. The company was originally incorporated in 1999 as Galapagos NV and rebranded to its current name in May 2026. It primarily serves the United States and European markets, as indicated by its focus on clinical trials and commercialization in these regions. Its collaboration with Gilead Sciences also suggests a global reach in drug development.